Extended-Interval Prophylaxis with Recombinant Factor IX FC Fusion Protein (rFIXFc) in Adults/Adolescents with Haemophilia B: Interim Results of the B-YOND Extension Study

被引：0
|
作者：
Mahlangu, J. [1 ,2 ]
Shapiro, A. D. [3 ]
Pasi, K. J. [4 ]
Ragni, M. V. [5 ]
Ozelo, M. C. [6 ]
Oldenburg, J. [7 ]
Matsushita, T. [8 ]
Baker, R. I. [9 ]
Yuan, H. [10 ]
Ramirez-Santiago, A. [10 ]
Pierce, G. F. [10 ]
Allen, G. [10 ]
Mei, B. [10 ]
机构：
[1] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa
[2] NHLS, Johannesburg, South Africa
[3] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
[4] Barts & London Queen Marys Sch Med & Dent, Royal London Haemophilia Ctr, London, England
[5] Univ Pittsburgh, Hemophilia Ctr Western Penn, Pittsburgh, PA USA
[6] Univ Estadual Campinas, INCT Sangue Hemoctr UNICAMP, Campinas, SP, Brazil
[7] Univ Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
[8] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan
[9] Murdoch Univ, Western Australia Ctr Thrombosis & Haemostasis, Perth, WA, Australia
[10] Biogen, Cambridge, MA USA
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P044
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [31] Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
    Powell, Jerry S.
    Pasi, K. John
    Ragni, Margaret V.
    Ozelo, Margareth C.
    Valentino, Leonard A.
    Mahlangu, Johnny N.
    Josephson, Neil C.
    Perry, David
    Manco-Johnson, Marilyn J.
    Apte, Shashikant
    Baker, Ross I.
    Chan, Godfrey C.
    Novitzky, Nicolas
    Wong, Raymond S.
    Krassova, Snejana
    Allen, Geoffrey
    Jiang, Haiyan
    Innes, Alison
    Li, Shuanglian
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Nugent, Karen
    Vigliani, Gloria
    Brennan, Aoife
    Luk, Alvin
    Pierce, Glenn F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2313 - 2323
  • [32] Immune tolerance induction using Fc-fusion-protein recombinant factor IX in severe haemophilia B
    Amid, Ali
    Perkins, Heather
    Gauthier, Julie
    Bonnefoy, Arnaud
    Carcao, Manuel
    Rivard, Georges-etienne
    Klaassen, Robert J.
    HAEMOPHILIA, 2021, 27 (06) : E776 - E779
  • [33] REAL-WORLD EFFECTIVENESS AND USAGE OF RECOMBINANT FACTOR IX FC FUSION PROTEIN (RFIXFC) FOR MANAGEMENT OF MAJOR/MINOR SURGERIES IN PATIENTS WITH HAEMOPHILIA B (HB) IN FRANCE: RESULTS FROM THE ONGOING B-SURE STUDY
    Castet, S.
    Chambost, H.
    Fouassier, M.
    Repesse, Y.
    d'Oiron, R.
    Barbay, V.
    Andersson, H.
    Martinez, C.
    Santagostino, E.
    HAEMOPHILIA, 2021, 27 : 115 - 116
  • [34] A prospective post-authorization safety surveillance study in Japanese hemophilia B patients with recombinant factor IX Fc fusion protein (rFIXFc)
    Hanabusa, Hideji
    Higasa, Satoshi
    Taki, Masashi
    Kobayashi, Masao
    Hashizume, Akio
    Makioka, Haruki
    Shiraishi, Mutsumi
    Hirakata, Toshiyuki
    HAEMOPHILIA, 2016, 22 : 52 - 52
  • [35] B-LONG: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor IX Fc Fusion Protein (rFIXFc)
    Powell, J.
    Ozelo, M. C.
    Pasi, J.
    Ragni, M.
    Valentino, L. A.
    Mahlangu, J.
    Manco-Johnson, M.
    Josephson, N.
    Perry, D.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 240 - 240
  • [36] B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B
    Ragni, Margaret
    Kulkarni, Roshni
    Pasi, K. John
    Fischer, Kathelijn
    Mahlangu, Johnny
    Shapiro, Amy
    Nolan, Beatrice
    Oldenburg, Johannes
    Matsushita, Tadashi
    Willemze, Annemieke
    Yuan, Huixing
    Rudin, Dan
    BLOOD, 2018, 132
  • [37] COST-EFFECTIVENESS OF RECOMBINANT FACTOR IX FC PROPHYLAXIS AND RECOMBINANT FACTOR IX ONDEMAND TREATMENT IN PATIENTS WITH HAEMOPHILIA B WITHOUT INHIBITORS
    Pochopien, M.
    Tytula, A.
    Toumi, M.
    Falk, A.
    Cioni, L.
    Hakimi, Z.
    Eriksson, D.
    VALUE IN HEALTH, 2022, 25 (12) : S73 - S74
  • [38] Long-term safety and efficacy of recombinant factor ix fusion protein (rIX-FP) in patients with haemophilia B: Interim results from an ongoing phase 3b extension study
    Santagostino, E.
    Pabinger, I.
    Brainsky, A.
    Li, Y.
    Seifert, W.
    HAEMOPHILIA, 2019, 25 : 80 - 81
  • [39] Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study
    Fischer, Kathelijn
    Kulkarni, Roshni
    Nolan, Beatrice
    Mahlangu, Johnny
    Rangarajan, Savita
    Gambino, Giulia
    Diao, Lei
    Ramirez-Santiago, Alejandra
    Pierce, Glenn F.
    Allen, Geoffrey
    LANCET HAEMATOLOGY, 2017, 4 (02): : E75 - E82
  • [40] Effect of Sampling Duration on Pharmacokinetic (PK) Parameters of Recombinant Factor IX FC Fusion Protein (rFIXFc) in the Phase 3 B-LONG Study
    Berntorp, E.
    Mei, B.
    Lethagen, S.
    Li, S.
    HAEMOPHILIA, 2016, 22 : 44 - 44
12345